With $4.5 billion in facility-specific investment, this project clears AFT's $100 million investment threshold (AFT includes any project meeting $100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Eli Lilly
- Industry
- Pharmaceuticals
- Location
- Lebanon, Indiana
- Investment
- $4.50B
- Permanent jobs announced
- 0
- Status
- Under Construction
- Announced
- May 6, 2026
- Opening timeline
- the Lebanon Advanced Therapies facility opened May 6, 2026, while the API site and the separately tracked Medicine Foundry remain under construction. Lilly has not supplied a new project-wide opening date for this expansion.
- Added to tracker
- Aug 30, 2026
Official references
- Lilly's May 6, 2026 additional Indiana manufacturing investment https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing
- Lilly additional Indiana manufacturing investment fact sheet https://investor.lilly.com/node/54216/pdf